tiprankstipranks
Trending News
More News >
MaaT Pharma (FR:MAAT)
:MAAT
France Market

MaaT Pharma (MAAT) Stock Statistics & Valuation Metrics

Compare
3 Followers

Total Valuation

MaaT Pharma has a market cap or net worth of €84.30M. The enterprise value is ―.
Market Cap€84.30M
Enterprise Value

Share Statistics

MaaT Pharma has 16,115,252 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,115,252
Owned by Insiders
Owned by Institutions1.03%

Financial Efficiency

MaaT Pharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee37.76K
Profits Per Employee-334.19K
Employee Count59
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of MaaT Pharma is ―. MaaT Pharma’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, MaaT Pharma had revenue of 2.23M and earned -19.72M in profits. Earnings per share was -1.73.
Revenue2.23M
Gross Profit1.66M
Operating Income-19.94M
Pretax Income-19.72M
Net Income-19.72M
EBITDA-19.74M
Earnings Per Share (EPS)-1.73

Cash Flow

In the last 12 months, operating cash flow was -21.00M and capital expenditures -1.05M, giving a free cash flow of -22.05M billion.
Operating Cash Flow-21.00M
Free Cash Flow-22.05M
Free Cash Flow per Share-1.37

Dividends & Yields

MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.52
52-Week Price Change-35.15%
50-Day Moving Average5.22
200-Day Moving Average6.72
Relative Strength Index (RSI)53.49
Average Volume (3m)10.71K

Important Dates

MaaT Pharma upcoming earnings date is Sep 16, 2025, Before Open (Confirmed).
Last Earnings DateMar 27, 2025
Next Earnings DateSep 16, 2025
Ex-Dividend Date

Financial Position

MaaT Pharma as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, MaaT Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate

Enterprise Valuation

MaaT Pharma EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

MaaT Pharma has €31.15M in cash and marketable securities with €17.17M in debt, giving a net cash position of -€13.98M billion.
Cash & Marketable Securities€31.15M
Total Debt€17.17M
Net Cash-€13.98M
Net Cash Per Share-€0.87
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for MaaT Pharma is €19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€19.00
Price Target Upside262.60% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast44.34%
EPS Growth Forecast-27.37%

Scores

Smart ScoreN/A
AI Score44
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis